G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
29 Noviembre 2023 - 7:37PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that an abstract exploring the long-term
impact of trilaciclib on survival outcomes in patients with
metastatic triple negative breast cancer (mTNBC) from the Company’s
Phase 2 trial (NCT02978716) will be presented in a poster session
during the upcoming 2023 San Antonio Breast Cancer Symposium
(SABCS), held December 5th through 9th in San Antonio, TX. A copy
of the poster will be made available on the G1 Therapeutics website
following the presentation here.
Results in the poster include:
- Median overall survival (OS) for
patients who received subsequent lines of anticancer therapy (SACT)
after discontinuation of study treatment was 32.7 months for
patients who had previously received trilaciclib prior to
gemcitabine/carboplatin (GCb) compared to 12.8 months for patients
who had previously received GCb only (no trilaciclib), with
increasing separation of survival curves over time.
- Improved survival and sustained
separation of curves was also observed in patients unable to
receive SACT, although the magnitude of benefit was smaller (median
9.4 months for patients who had previously received trilaciclib vs
5.4 months for patients who had previously received chemotherapy
alone).
- Notably, median OS from the start
of the first SACT was 14.0 months in patients who had previously
received trilaciclib prior to GCb compared to 5.8 months in
patients who received GCb only (no trilaciclib).
- For patients who received any SACT
after discontinuation of study treatment, demographics and clinical
characteristics including, time from end of study treatment to
first SACT, and type of SACT were balanced between the prior
trilaciclib (n=43) and prior GCb-only (n=20) groups.
“These results describe the long-term survival benefits of
treatment with trilaciclib in patients with triple negative breast
cancer that participated in our Phase 2 trial,” said Raj Malik,
M.D., Chief Medical Officer of G1 Therapeutics. “The survival
benefit appears to extend well beyond the initial treatment with
trilaciclib and chemotherapy. Importantly, patients who had
previously received trilaciclib continue to benefit with subsequent
therapies, resulting in substantially longer survival than patients
who had previously received chemotherapy alone. We believe this is
likely due to preservation of bone marrow and immune function,
resulting in improved long term immune surveillance. We look
forward to sharing these results with the oncology community, as we
assess the impact of trilaciclib on overall survival in our ongoing
pivotal Phase 3 mTNBC and Phase 2 ADC trials.”
Poster Presentation Details: Patients With
Metastatic Triple-Negative Breast Cancer who Receive Trilaciclib
Prior to Cytotoxic Chemotherapy Exhibit Improved Survival After
Receiving Subsequent Anticancer Therapy. O’Shaughnessy, J. et al.
Presentation ID (poster and abstract number): PO2-06-12. Poster
Session 2 Wednesday, December 6, 2023. 5:00 PM – 7:00 PM CDT
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). The Company is
also evaluating therapies in combination with cytotoxic therapies
and/or immunotherapy in areas of high unmet need including
triple-negative breast cancer and extensive stage small cell lung
cancer. G1’s goal is to provide innovative therapeutic advances for
people living with cancer. G1 is based in Research Triangle Park,
N.C. For additional information, please visit
http://www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this press release include, but are
not limited to, the long-term survival benefit of trilaciclib, and
the ability of benefits of trilaciclib to extend beyond treatment
with trilaciclib and chemotherapy, and that these benefits are
likely due to preservation of the lymphoid lineage and an expanded
memory T-cell pool resulting in improved long term immune
surveillance. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause the company’s
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
the company’s filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained therein
and include, but are not limited to, the company’s dependence on
the commercial success of COSELA (trilaciclib); the development and
commercialization of new drug products is highly competitive; the
company’s ability to complete clinical trials for, obtain approvals
for and commercialize any of its product candidates; the company’s
initial success in ongoing clinical trials may not be indicative of
results obtained when these trials are completed or in later stage
trials; the inherent uncertainties associated with developing new
products or technologies and operating as a commercial-stage
company; and market conditions. Except as required by law, the
company assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
G1 Therapeutics Contacts:
Will RobertsVice President, Investor Relations & Corporate
Communications919-907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024